HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Raises Price Target to $24
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and raises the price target from $22 to $24.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and raises the price target from $22 to $24.